| David H Workman Ix, MD | |
|
1214 W Sun River Dr, Riverton, UT 84065-6196 | |
| (801) 309-1476 | |
| Not Available |
| Full Name | David H Workman Ix |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 37 Years |
| Location | 1214 W Sun River Dr, Riverton, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659329449 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 1786741205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Timpanogos Regional Hospital | Orem, UT | Hospital |
| Utah Valley Hospital | Provo, UT | Hospital |
| Holladay Healthcare Center | Salt lake city, UT | Nursing home |
| City Creek Post Acute | Salt lake city, UT | Nursing home |
| Heritage Care Center | American fork, UT | Nursing home |
| Mission At Alpine Rehabilitation Center | Pleasant grove, UT | Nursing home |
| Willow Wood Care Center | Salt lake city, UT | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Utah Regional Hospitalists Llc | 4789807165 | 145 |
News Archive
Law enforcement officers fanned out across five states Friday in what federal officials called the largest Medicare fraud bust ever conducted. Nearly 100 people were indicted in frauds that totaled $251 million.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves - as well as the largest, most scientifically rigorous study to examine the question - reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer.
Neuroscientists at the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia will begin a clinical trial testing a new type of drug that attacks amyloid, the protein substance that accumulates in the brains of Alzheimer's disease patients.
› Verified 3 days ago
| Entity Name | David H Workman Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760743421 PECOS PAC ID: 5193972925 Enrollment ID: O20120829000468 |
News Archive
Law enforcement officers fanned out across five states Friday in what federal officials called the largest Medicare fraud bust ever conducted. Nearly 100 people were indicted in frauds that totaled $251 million.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves - as well as the largest, most scientifically rigorous study to examine the question - reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer.
Neuroscientists at the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia will begin a clinical trial testing a new type of drug that attacks amyloid, the protein substance that accumulates in the brains of Alzheimer's disease patients.
› Verified 3 days ago
| Entity Name | Utah Regional Hospitalists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962821223 PECOS PAC ID: 4789807165 Enrollment ID: O20140604000236 |
News Archive
Law enforcement officers fanned out across five states Friday in what federal officials called the largest Medicare fraud bust ever conducted. Nearly 100 people were indicted in frauds that totaled $251 million.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves - as well as the largest, most scientifically rigorous study to examine the question - reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer.
Neuroscientists at the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia will begin a clinical trial testing a new type of drug that attacks amyloid, the protein substance that accumulates in the brains of Alzheimer's disease patients.
› Verified 3 days ago
| Entity Name | Centre Health Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851917496 PECOS PAC ID: 7214356997 Enrollment ID: O20200929003556 |
News Archive
Law enforcement officers fanned out across five states Friday in what federal officials called the largest Medicare fraud bust ever conducted. Nearly 100 people were indicted in frauds that totaled $251 million.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves - as well as the largest, most scientifically rigorous study to examine the question - reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer.
Neuroscientists at the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia will begin a clinical trial testing a new type of drug that attacks amyloid, the protein substance that accumulates in the brains of Alzheimer's disease patients.
› Verified 3 days ago
| Entity Name | Usacs Long Term Care Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881373090 PECOS PAC ID: 2466806062 Enrollment ID: O20231018003756 |
News Archive
Law enforcement officers fanned out across five states Friday in what federal officials called the largest Medicare fraud bust ever conducted. Nearly 100 people were indicted in frauds that totaled $251 million.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves - as well as the largest, most scientifically rigorous study to examine the question - reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer.
Neuroscientists at the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia will begin a clinical trial testing a new type of drug that attacks amyloid, the protein substance that accumulates in the brains of Alzheimer's disease patients.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David H Workman Ix, MD 1214 W Sun River Dr, Riverton, UT 84065-6196 Ph: (801) 309-1476 | David H Workman Ix, MD 1214 W Sun River Dr, Riverton, UT 84065-6196 Ph: (801) 309-1476 |
News Archive
Law enforcement officers fanned out across five states Friday in what federal officials called the largest Medicare fraud bust ever conducted. Nearly 100 people were indicted in frauds that totaled $251 million.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves - as well as the largest, most scientifically rigorous study to examine the question - reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer.
Neuroscientists at the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia will begin a clinical trial testing a new type of drug that attacks amyloid, the protein substance that accumulates in the brains of Alzheimer's disease patients.
› Verified 3 days ago
Dr. Lindsay Malechek Klimes, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3723 W 12600 S, Riverton, UT 84065 Phone: 801-507-4384 | |
Dr. Robert D Williams, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1288 West 12700 South, Riverton, UT 84065 Phone: 801-253-0291 Fax: 801-446-2745 | |
Adam Michael Howard, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3723 W 12600 S Ste 150, Riverton, UT 84065 Phone: 801-285-4560 | |
Melanie Arrington, FNP Family Medicine Medicare: Medicare Enrolled Practice Location: 1420 W 12600 S Ste 102, Riverton, UT 84065 Phone: 801-254-4600 Fax: 801-254-9670 | |
Stephen B Devenport, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12391 S 4000 W, Riverton, UT 84065 Phone: 801-302-1760 Fax: 801-302-1714 | |
David W Brinton, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3859 W 12600 S, Riverton, UT 84065 Phone: 801-302-7300 Fax: 801-302-7301 | |
Dr. Don Preston Allred, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1756 Park Ave, Riverton, UT 84065 Phone: 801-254-0309 Fax: 801-254-1012 |